Charles Schwab’s Acumen Pharmaceuticals ABOS Stock Holding History

Charles Schwab’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Buy	+115,099	New	+$284K	﹤0.01%	3328
2025 Q2	–	Sell	-116,902	Closed	-$129K	–	3495
2025 Q1	$129K	Sell	116,902 -9,845	-8%	-$14.1K	﹤0.01%	3308
2024 Q4	$218K	Buy	126,747 +18,004	+17%	+$43.3K	﹤0.01%	3317
2024 Q3	$270K	Hold	108,743	–	–	﹤0.01%	3304
2024 Q2	$263K	Buy	+108,743	New	+$346K	﹤0.01%	3397
2022 Q2	–	Sell	-63,251	Closed	-$248K	–	3537
2022 Q1	$248K	Buy	63,251 +39,214	+163%	+$213K	﹤0.01%	3270
2021 Q4	$163K	Hold	24,037	–	–	﹤0.01%	3386
2021 Q3	$358K	Buy	+24,037	New	+$400K	﹤0.01%	3226

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Charles Schwab's ABOS Position: Q2 2026 in Review

Charles Schwab opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 115,099 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #3328 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ABOS as recently as Q1 2025.

Charles Schwab first reported a position in ABOS in Q3 2021 and has held it in 8 quarters since. The position peaked at $358K in Q3 2021. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Charles Schwab held 115,099 shares of Acumen Pharmaceuticals worth $307K as of Q2 2026.
Acumen Pharmaceuticals was a new Charles Schwab position in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3328 holding.
Charles Schwab first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Charles Schwab's Acumen Pharmaceuticals position peaked at $358K in Q3 2021.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.